Charles River Laboratories International's (CRL) mid-term sales growth has structurally slowed down, a view that is supported by recent results and outlook, peer read-across, pricing trends and updated market analysis, UBS Securities said in a note Friday.
The brokerage said it sees various pressures to the mid-term sales growth in the company's discovery and safety assessment segment, which comprises about 60% of its sales.
Among these pressures are budget pressures at big pharma and underappreciated pricing pressures, UBS said.
"We remain constructive on Charles River's positioning as a key enabler to biopharma, and its opportunity to execute on cost reductions," UBS said.
UBS downgraded Charles River to neutral from buy and cut its price target to $185 from $250.
Price: 165.17, Change: -0.63, Percent Change: -0.38
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。